Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 76 to 90 of 187 results for prostate cancer

  1. NICE encourages further research into focal cryoablation for localised prostate cancer. This should take the form of controlled studies comparing the procedure against other forms of management. Studies should clearly define patient selection criteria and should report outcomes including local recurrence in the long term.

    NICE encourages further research into focal cryoablation for localised prostate cancer. This should take the form of controlled studies...

    Research recommendation
    Published
    9 June 2015

  2. NICE newsletters and alerts

    Subscribe to NICE newsletters and alerts for the latest healthcare guidance, clinical updates, and evidence-based resources across health and social care.

  3. Intraoperative red blood cell salvage during radical prostatectomy or radical cystectomy (HTG167)

    Evidence-based recommendations on intraoperative red blood cell salvage during radical prostatectomy or radical cystectomy. This involves collecting the solid components of the blood lost during an operation and transfusing it back to the same patient.

    HealthTech guidance
    Published
    26 April 2008
    View recommendations

    Sections for HTG167

  4. Axonics sacral neuromodulation system for treating refractory overactive bladder (HTG554)

    Evidence-based recommendations on Axonics sacral neuromodulation system for treating refractory overactive bladder.

    HealthTech guidance
    Published
    3 September 2020
    View recommendations

    Sections for HTG554

  5. Rezum for treating lower urinary tract symptoms secondary to benign prostatic hyperplasia (HTG545)

    Evidence-based recommendations on Rezum for treating lower urinary tract symptoms secondary to benign prostatic hyperplasia.

    HealthTech guidance
    Published
    24 June 2020
    View recommendations

    Sections for HTG545

  6. Microwave ablation for primary or metastatic cancer in the lung (HTG609)

    Evidence-based recommendations on microwave ablation for primary or metastatic cancer in the lung in adults. This involves inserting a probe into the lung, through the skin of the chest, to send microwaves into the cancer cells. This produces heat, aiming to destroy the cancer (ablation).

    HealthTech guidance
    Published
    2 February 2022
    View recommendations

    Sections for HTG609

  7. Evidence on the safety of focal therapy using high-intensity focused ultrasound for localised prostate cancer is adequate, but evidence on its efficacy is limited. Therefore, this procedure should only be used with special arrangements for clinical governance, consent, and audit or research. Find out what special arrangements mean on the NICE interventional procedures guidance page.

    focal therapy using high-intensity focused ultrasound for localised prostate cancer is adequate, but evidence on its efficacy is...

    Research recommendation
    Published
    5 May 2023

  8. Evidence on the safety and efficacy of biodegradable spacer insertion to reduce rectal toxicity during radiotherapy for prostate cancer is limited in quality. Therefore, this procedure should only be used with special arrangements for clinical governance, consent, and audit or research. Find out what special arrangements mean on the NICE interventional procedures guidance page.

    spacer insertion to reduce rectal toxicity during radiotherapy for prostate cancer is limited in quality. Therefore, this procedure...

    Research recommendation
    Published
    9 March 2023

  9. Further research is recommended to resolve uncertainties about the clinical effectiveness of degarelix compared with luteinising hormone-releasing hormone (LHRH) agonists such as leuprorelin, goserelin and triptorelin for treating advanced hormone-dependent prostate cancer, particularly in subgroups of people with preexisting cardiovascular disease, people with skeletal (including spinal) metastases and people with impending ureteric and urethral obstruction. Research should be planned as part of well-conducted randomised clinical trials.

    goserelin and triptorelin for treating advanced hormone-dependent prostate cancer, particularly in subgroups of people with preexisting...

    Research recommendation
    Published
    17 October 2016

  10. Laparoscopic prostatectomy for benign prostatic obstruction (HTG176)

    Evidence-based recommendations on laparoscopic prostatectomy for benign prostatic obstruction. This involves removing the prostate through small cuts in the abdomen, using a fine telescope to see inside the body (keyhole surgery).

    HealthTech guidance
    Published
    26 November 2008
    View recommendations

    Sections for HTG176

  11. Primary care testing: Diagnostic accuracy studies of tests accessible to primary care should be carried out for a given cancer in symptomatic people. Priority areas for research should include tests for people with cough, non-visible haematuria, suspected prostate cancer, suspected pancreatic cancer, suspected cancer in childhood and young people and other suspected rare cancers. Outcomes of interest are the performance characteristics of the test, particularly sensitivity, specificity and positive and negative predictive values.

    studies of tests accessible to primary care should be carried out for a given cancer in symptomatic people. Priority areas for research...

    Research recommendation
    Published
    7 January 2022

  12. What is the most clinically and cost-effective follow‑up protocol for people with prostate cancer who have had radical treatment, with specific regard to risk stratification, duration of follow‑up, frequency of follow‑up appointments, the type of examination or blood tests, and the roles of primary and secondary care in follow‑up?

    most clinically and cost-effective follow‑up protocol for people with prostate cancer who have had radical treatment, with specific...

    Research recommendation
    Published
    25 October 2019

  13. Artificial intelligence (AI) technologies to assist histopathology for prostate cancer diagnosis [ID6684]

    In development Reference number: GID-TA11958 Expected publication date: TBC

    Technology appraisal guidance
    In development

  14. UroLift for treating lower urinary tract symptoms of benign prostatic hyperplasia (HTG578)

    Evidence-based recommendations on UroLift for treating lower urinary tract symptoms of benign prostatic hyperplasia.

    HealthTech guidance
    Published
    4 May 2021
    View recommendations

    Sections for HTG578

  15. Spinal metastases and metastatic spinal cord compression (NG234)

    This guideline covers recognition, referral, investigation and management of spinal metastases and metastatic spinal cord compression (MSCC). It is also relevant for direct malignant infiltration of the spine and associated cord compression. It aims to improve early diagnosis and treatment to prevent neurological injury and improve prognosis.

    NICE guideline
    Published
    6 September 2023
    View recommendations

    Sections for NG234